RAF1 and non-small cell lung carcinoma: This study compared the type I RAF inhibitor, Dabrafenib, and the type II RAF inhibitor, AZ628, as single agents and in combination with the MEK inhibitor, Trametinib, in both transfected HEK293T cells overexpressing several RAF derivatives and a BRAF mutant NSCLC derived cell line model.